Srinivasan Parthiban (VINGYANI, India)
Deep learning is hot, making waves, delivering results, and is somewhat of a buzzword today. There is a desire to apply deep learning to anything that is digital. Unlike the brain, these artificial neural networks have a very strict predefined structure. The brain is made up of neurons that talk to each other via electrical and chemical signals. We do not differentiate between these two types of signals in artificial neural networks. They are essentially a series of advanced statistics based exercises that review the past to indicate the likely future. Another buzzword that was used for the last few years across all industries is “big data”. In biomedical and health sciences, both unstructured and structured information constitute "big data". On the one hand deep learning needs lot of data whereas “big data" has value only when it generates actionable insight. Given this, these two areas are destined to be married. The couple is made for each other. The time is ripe now for a synergistic association that will benefit the pharmaceutical companies. It may be only a short time before we have vice presidents of machine learning or deep learning in pharmaceutical and biotechnology companies. This presentation will review the prominent deep learning methods and discuss these techniques for their usefulness in biomedical and health informatics.